About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

TERMINATEDNCT01761682

Acute Lymphoblastic Leukemia Registry at Asan Medical Center

The investigators would like to propose a prospective longitudinal observational cohort study for patients who will be diagnosed and/or treated for acute lymphoblastic leukemia at Asan Medical Center,...

Lead sponsor: Asan Medical Center•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Asan Medical Center

1. Acquisition of informed concent form 2. Data acquisition from medical record including * demographic / disease-associated factors * details of treatment, and its results * complications during treatment * genetic data * survival outcome (upto 10 years) 3. Accumulation of data for 30 years 4. Use of data for other retrospective analysis (including Asan Medical center Cell Banking basic data)

Age

15 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•All patients who are diagnosed and/or treated as acute lymphoblastic leukemia at Asan Medical Center (including biphenotypic acute leukemia with Philadelphila-positive, Burkitt leukemia/lymphoma)
•15 years of age and over
•All patients who give written consent according to guidelines at Asan Medical Center committee on human research

Exclusion Criteria

•Patients who refuse to give consent to registering

Related studies

RECRUITINGPhase 3

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

NCT04307576 · Leukemia, Acute Lymphoblastic

RECRUITINGPhase 2/3

Newly-diagnosed Pediatric T-cell ALL Protocol

NCT06855810 · Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, and more

RECRUITINGPhase 1/2

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

NCT06880913 · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

RECRUITINGPhase 1/2

CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma

NCT06101381 · Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin

Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention

NCT06626893 · Myeloid Leukemia, Acute, Leukemia, Acute Lymphoblastic

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 20, 2018Terms

Trial snapshot

StatusTERMINATED

Phase—

Enrollment200

Start dateJan 2013

Last updatedJul 20, 2018

Condition

Leukemia, Acute Lymphoblastic Precursor B-Cell Lymphoblastic Leukemia Leukemia, Biphenotypic, Acute Leukemia, Lymphoblastic, Acute, Philadelphia-Positive Lymphoblastic Lymphoma

Locations shown

Asan Medical Center

Seoul

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 20, 2018Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions